Navigation Links
Novel LABA/LAMA Products Will Capture Greater Market Share than the LABA/ICS or LAMA Drug Classes by 2022
Date:8/28/2013

BURLINGTON, Mass., Aug. 28, 2013 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that the drug market for chronic obstructive pulmonary disease (COPD) therapies will see the emergence of a new drug class that will drive sales through 2022. Currently, the COPD market is dominated by Boehringer Ingelheim/Pfizer's long-acting muscarinic antagonist (LAMA) Spiriva and GlaxoSmithKline's long-acting beta2 agonist (LABA)/inhaled corticosteroid (ICS) Advair/Seretide/Adoair. In 2012, total sales of these two market leaders constituted nearly two-thirds of COPD sales. However, following the launch of new agents, particularly those that offer advantages in dosing, their combined market share will diminish to less than 15 percent in 2022.

The Pharmacor advisory service entitled Chronic Obstructive Pulmonary Disease finds that the market for COPD will increase from nearly $10 billion in 2012 to $14 billion in 2022 in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan. Five fixed-dose combination inhalers comprised of a LABA and a LAMA are forecasted to launch over the next ten years and this new drug class will collectively garner over 35 percent market share in 2022. Among these novel combinations, GlaxoSmithKline/Theravance's Anoro and Boehringer Ingelheim's olodaterol/tiotropium are expected to experience the greatest success, totaling nearly $4 billion in major-market sales in 2022.

"The clinical trial data for LABA/LAMAs continue to be promising and these combination products will provide the convenience of delivering the two major bronchodilator classes that are recommended as first-line maintenance options in treatment guidelines," said Decision Resources Senior Director Joanna Kim, M.Ed.

The findings also reveal that GlaxoSmithKline/Theravance's Breo/Relvar will perform strongly and act as another key growth driver, alongside the LABA/LAMAs, in the COPD market. Breo/Relvar's once-daily administration will be the first to offer dosing improvement over Advair which, together with efficacy that is comparable to Advair, will challenge Advair's dominance in all major markets.

About Decision Resources
Decision Resources (www.decisionresources.com) is a world leader in market research publications, advisory services and consulting designed to help clients shape strategy, allocate resources and master their chosen markets. Decision Resources is a Decision Resources Group company.

About Decision Resources Group
Decision Resources Group is a cohesive portfolio of companies that offers best-in-class, high-value information and insights on important sectors of the healthcare industry. Clients rely on this analysis and data to make informed decisions. Please visit Decision Resources Group at www.DecisionResourcesGroup.com.

All company, brand, or product names contained in this document may be trademarks or registered trademarks of their respective holders.


'/>"/>
SOURCE Decision Resources
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. The Dyslipidemia Market Will Grow to $31 Billion in 2022, Driven by the Launch of Novel Therapies
2. Novel Use of Pressure BioSciences Patented PCT Platform Offers New Insights into Protein Structure and Function, New Tool for Biomarker Discovery and Rational Drug Design
3. Lakewood-Amedex Announces Its Novel Bisphosphocin Class Of Antimicrobials Are Active Against NDM-1 Positive Bacterial Strains
4. Naurex Announces Issuance Of New Patent For Novel Antidepressant GLYX-13
5. NGM Biopharmaceuticals Secures $50 Million in Series C Financing to Advance its Portfolio of Novel Therapies for Diabetes and Obesity
6. Follow-up Phase II Data Analysis Adds to Body of Evidence for Investigational Novel Basal Insulin, LY2605541
7. NextDocs and Novella to Present on eTMF at DIA 2013
8. KemPharm, Inc. Receives Patent from the USPTO for Novel Pain Drug Candidate, KP201
9. Adult and Adolescent Vaccines Market to 2018 Report - Promising Novel Candidates in Late-Stage Development and Prevnar Approval for Use in Adults to Drive Growth
10. Quantum Materials Tetrapod Quantum Dots Break Kashas Rule: Enhanced Performance Enables Commercialization of Novel Discovery
11. ImmunGene and Collaborators Report Positive Results in Pre-clinical Studies of Novel Anti-CD20 Antibody-Interferon Alpha Fusion Protein
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2017)... 2017  BDI Group subsidiary Pathway Purchasing Network, ... organization serving specialty pharmacies, home infusion companies and ... significant, value-added member programs designed to help organizations ... and improve access and affordability for patients who ... Pathway has worked ...
(Date:7/10/2017)... , July 10, 2017 Locus Biosciences ... Note to support the development of CRISPR-Cas3 antimicrobial therapeutics. ... Limited, a leading Chinese Internet services provider, and joined ... advance multiple infectious disease product programs targeting antibiotic resistant ... Founded by Dr. Rodolphe Barrangou ...
(Date:7/5/2017)... , July 5, 2017 Wolfmet 3D ... answer as physics and manufacturing combine to progress molecular radiotherapy ... existing SPECT systems are unable to accurately quantify the radiation ... limited information regarding the success of this radiotherapy treatment has ... ...
Breaking Medicine Technology:
(Date:7/21/2017)... (PRWEB) , ... July 21, 2017 , ... ... management assistance and financial planning services to families and business owners in northern ... event that promises to provide support to area adults with developmental challenges. , ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... selected to renovate and improve the Ramsey County Medical Examiners Facility located in ... Hospital, the $2.5 million project is scheduled to start in late 2017/early 2018. ...
(Date:7/21/2017)... , ... July 21, 2017 , ... ... and Theater of Witness , was awarded a $300,000 grant from ... program which fosters empathy, comfort with ambiguity and the recognition of one’s own ...
(Date:7/21/2017)... ... 2017 , ... Bernard R. Bach, Jr., MD, orthopaedic surgeon at Rush University ... of Sports Medicine (AOSSM) , received the 2017 Robert E. Leach Sports Medicine Leadership ... This prestigious award is given annually to honor those who have made a significant ...
(Date:7/21/2017)... ... July 21, 2017 , ... Yisrayl Hawkins, Pastor and Overseer at The House of ... of violence and aggression to solve problems and pleads with world leaders to be more ... forces do not bring peace. He says there is a peaceful and positive way to ...
Breaking Medicine News(10 mins):